Welcome to our dedicated page for Ascentage Pharma Group International SEC filings (Ticker: AAPG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ascentage Pharma Group International (NASDAQ: AAPG) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. Ascentage Pharma files annual reports on Form 20‑F and current reports on Form 6‑K under the Securities Exchange Act of 1934, reflecting its status as a NASDAQ‑listed biopharmaceutical company with operations in oncology and hematology.
Recent Form 6‑K filings have furnished press releases on a range of material topics, including pivotal Phase II and Phase III clinical data for Lisaftoclax and olverembatinib, regulatory clearances from the U.S. FDA and EMA for global registrational studies such as POLARIS‑1 and GLORA, publication of olverembatinib data in gastrointestinal stromal tumors, investor conference participation, interim financial results and business updates, and corporate governance items such as indemnification agreements and interest payments related to top‑up placements. These filings help investors understand the progress of Ascentage Pharma’s apoptotic pathway inhibitors, BCR‑ABL1 inhibitor programs, and protein degrader pipeline.
On Stock Titan, each new AAPG filing is captured from EDGAR and presented with AI‑generated highlights to explain the context and key points in clear language. Users can review Form 6‑K submissions related to clinical milestones, financing activities, and board decisions, and can connect these disclosures to the company’s broader oncology strategy. While Ascentage Pharma’s core SEC reporting currently emphasizes 6‑K updates, investors can also reference its Form 20‑F annual report for a more detailed discussion of risk factors, business overview, and financial statements.
In addition, this page offers quick access to historical filings so that readers can trace how Ascentage Pharma’s hematology and solid tumor programs, global partnerships, and capital markets activities have evolved over time. AI‑assisted summaries help reduce the time needed to interpret lengthy documents, highlighting items such as major clinical trial announcements, regulatory interactions, and key corporate actions disclosed in AAPG’s SEC submissions.
Ascentage Pharma Group International has called a board meeting for March 25, 2026. At this meeting, the board plans to review and, if appropriate, approve the Group’s annual results for the year ended December 31, 2025 and consider declaring a final dividend. The notice also confirms the current composition of the board, including Chairman and Executive Director Dr. Yang Dajun and a mix of non-executive and independent non-executive directors.
Ascentage Pharma Group International will release its full year 2025 unaudited financial results and provide business updates on March 25, 2026 at 7:00 pm EDT / 7:00 am HKT. The company will host investor webcasts with Q&A in both Mandarin and English, led by management.
Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved drugs Olverembatinib and Lisaftoclax. It is running multiple registrational Phase III trials and maintains partnerships with major pharma companies and leading research institutions.
Ascentage Pharma Group International filed a report noting that its management will participate in three upcoming investor conferences. The related presentations and fireside chats will be available via webcasts on the Events page in the Investor Relations section of the company’s website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies, including its approved products Olverembatinib for chronic myeloid leukemia and Lisaftoclax for certain blood cancers, alongside multiple global Phase III trials and collaborations with major pharmaceutical companies and leading research institutions.
Ascentage Pharma Group International furnished a report highlighting its upcoming participation in the Guggenheim Emerging Outlook: Biotech Summit 2026. Company management will join a fireside chat at 9:30 a.m. EST on Thursday, February 12, with a live webcast available through the Events page of its investor relations website.
The filing also reiterates that Ascentage Pharma is a global, commercial-stage biopharmaceutical company focused on novel cancer therapies. Its lead drug Olverembatinib is approved in China for multiple chronic myeloid leukemia indications and covered by the China National Reimbursement Drug List. A second approved product, Lisaftoclax, treats certain chronic lymphocytic leukemia/small lymphocytic lymphoma patients and supports several global registrational Phase III trials in hematologic malignancies and myelodysplastic syndromes.
Ascentage Pharma Group International filed a Form 6-K to share that its BTK-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the China Center for Drug Evaluation (CDE). This follows a prior IND clearance from the U.S. Food and Drug Administration.
The company plans a multicenter, open-label Phase I trial in patients with relapsed or refractory hematologic malignancies to assess safety, tolerability, pharmacokinetics, and preliminary efficacy. APG-3288, built on Ascentage’s PROTAC technology, is designed to degrade both wild-type BTK and multiple resistance-associated BTK mutants, potentially addressing treatment-resistant B‑cell cancers and complementing its existing hematology portfolio, including Olverembatinib and Lisaftoclax in China.
Ascentage Pharma Group International provided an update on its 2025 milestones and outlined its global innovation strategy for 2026 during a presentation at the 44th Annual J.P. Morgan Healthcare Conference.
The company highlighted commercial progress of its two core hematology products, Olverembatinib and Lisaftoclax, which it describes as driving a dual-engine growth model, alongside multiple global registrational Phase III trials in blood cancers and solid tumors.
Ascentage Pharma also announced U.S. FDA IND clearance for APG-3288, a next-generation BTK protein degrader developed on its PROTAC platform, and discussed advancing additional candidates including APG-5918, APG-2449, Alrizomadlin, and Pelcitoclax, with planned 2026 milestones across clinical development, commercialization in China, and early-stage global studies, while emphasizing that these products remain investigational outside approved indications.
Ascentage Pharma Group International filed a Form 6-K to share that the U.S. Food and Drug Administration has granted investigational new drug (IND) clearance for APG-3288, a novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader. APG-3288, developed using the company’s PROTAC technology, is designed to degrade both wild-type and mutant BTK associated with resistance to existing BTK inhibitors.
The company will conduct a global, multicenter, open-label Phase I study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-3288 in patients with relapsed or refractory hematologic and B-cell malignancies. Ascentage highlights this clearance as a major expansion of its innovative pipeline and a strategic step in BTK-targeted therapies, complementing its existing approved products Olverembatinib and Lisaftoclax.
Ascentage Pharma Group International submitted a Form 6-K stating that on December 17, 2025 it issued a press release titled “Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference.” The report’s primary purpose is to furnish this press release as Exhibit 99.1 for U.S. investors.
Ascentage Pharma Group International furnished a Form 6-K highlighting two scientific updates for its Bcl-2 inhibitor lisaftoclax. The company reported that pivotal China registrational study data for lisaftoclax were presented in an oral report at the 2025 American Society of Hematology (ASH) Annual Meeting.
Ascentage also noted encouraging data from a Phase Ib/II study of lisaftoclax in venetoclax‑exposed patients with myeloid malignancies, which were shared at ASH 2025. Full details of these results are contained in press releases attached as Exhibits 99.1 and 99.2.
Ascentage Pharma Group International submitted a Form 6-K as a foreign private issuer for November 2025. The report mainly notes that on November 24, 2025 the company issued a press release titled “Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy”. A copy of this press release is furnished as Exhibit 99.1, making the scientific and clinical update available to investors through the U.S. disclosure system.